[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364944-105":59,"doc-detail-364944-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-and-function-validation-of-p2rx4-as-a-novel-cancer-biomarker-in-pan-cancer-analysis","The role and function validation of P2RX4 as a novel cancer biomarker in pan-cancer analysis","","Purinergic Receptor P2X4 (P2RX4) is investigated as a pan-cancer biomarker by integrating expression, gene mutation, immune infiltration, pathway enrichment, and prognostic analyses across multiple public databases including TCGA, GTEx, GEO, TIMER2, cBioportal, and Metascape. Experimental validation uses Western blot and RT-qPCR in liver hepatocellular carcinoma and paracancer tissues, plus functional assays after P2RX4 knockin or knockdown in glioblastoma and prostate cancer cells. Findings link elevated P2RX4 to worse overall and disease-free survival, fibroblast and CD8+ infiltration, autophagy-related pathways, and suppressed viability and migration upon P2RX4 inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-and-function-validation-of-p2rx4-as-a-novel-cancer-biomarker-in-pan-cancer-analysis/364944/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-and-function-validation-of-p2rx4-as-a-novel-cancer-biomarker-in-pan-cancer-analysis/364944.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data sources and analyses are used to study P2RX4 across cancers?","Question",{"text":112,"@type":113},"The study integrates expression levels, gene mutations, immune infiltration, pathway enrichment, and prognostic value using TCGA, GTEx, GEO, TIMER2, cBioportal, and Metascape, followed by analyses across 33 tumor types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was P2RX4 experimentally validated in specific cancer tissues and cell models?",{"text":117,"@type":113},"P2RX4 expression in liver hepatocellular carcinoma and paracancer samples was measured by Western blot and RT-qPCR. Functional cell studies used knockin in U251 and PC3 cells and assessed viability, apoptosis, migration, and invasion with CCK-8, flow cytometry, wound healing, and Transwell assays.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical significance does P2RX4 show in the pan-cancer results?",{"text":121,"@type":113},"Higher P2RX4 expression is reported in most cancers and predicts poorer overall survival and disease-free survival. The expression correlates positively with cancer-associated fibroblasts and CD8+ cell infiltration, and links to unfavorable prognosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},364944,1790210751,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe role and function validation of P2RX4 as a novel cancer biomarker in pan-cancer analysis  \nXiaoyuan Qiao1, Chunyan Wang2 & Jun Ma3􀀍  \nPurinergic Receptor P2X4 (P2RX4) is implicated in the carcinogenesis of several cancers, but no extensive study on its role in different forms of cancer. Expression level, gene mutation, immune infiltration, pathway enrichment, and prognostic value analysis of P2RX4 were performed based on multiple publicly available databases such as TCGA, GTEx, GEO, TIMER2, cBioportal, and Metascape databases. Western blot and RT-qPCR were used to identify P2RX4 expression in liver hepatocellular carcinoma (LIHC) and paracancer samples. P2RX4 was knocked in glioblastoma cell line (U251) and prostate cancer cell line (PC3), and its effects on cell viability, apoptosis, migration and invasion were investigated through cell counting kit-8 assay, flow cytometry, wound healing and trasnwell assays, respectively. P2RX4 expression was elevated in most cancers, which predicted poor overall survival and disease-free survival. Mutations in P2RX4 were predominantly found in Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (> 4%) . P2RX4 expression showed a positive correlation with the infiltration levels of cancer-associated fibroblasts and CD8 + cells in multiple tumor types. Functional enrichment analysis indicated that P2RX4 is closely related to autophagy, protein modification or intracellular trafficking. P2RX4 was highly expressed in LIHC compared to paracancerous tissues. Knockdown of P2RX4 suppressed cell viability, migration, invasion, and promoted cell apoptosis of U251 and  \nPC3 cells. Overexpression of P2RX4 occurred in multi cancers, and was connected to an unfavorable prognosis. This pan-cancer analysis highlighted the predictive value and tumorigenic role of P2RX4 .  \nKeywords Biomarker, P2RX4, Immune infiltration, Prognosis, Pan-cancer  \nCancer is the main cause of sickness and mortality worldwide, with enormous health and economic consequences for society1. As per the “Global cancer statistics 2022” report, cancer has led to 9.7 million deaths, with nearly 20 million new cases confirmed worldwide2. Despite advancements in multimodal therapies—including targeted therapies and immunotherapies—the heterogeneity of tumors and the emergence of treatment resistance continue to limit clinical outcomes3. Early diagnosis and precision medicine are critical for improving patient survival, yet the lack of robust biomarkers with broad applicability across cancer types remains a significant challenge4. Given the complexity of carcinogenesis, it is required to undertake a pan-cancer expression research of any potential gene, examine its connection to clinical outcome, and investigate probable molecular explanations5.  \nPurinergic Receptor P2X 4 (P2RX4), an ATP-gated ion channel, is increasingly recognized for its multifaceted roles in biological processes, including inflammatory pain6, neuropathic pain following nerve damage7,8, T-cell migration9, and cardiac function10. P2RX4 is also implicated in activated microglia survival, as well as memory issues in in type 2 diabetic rats11. Recent studies underscore its oncogenic potential. In prostate cancer, the pharmacological inhibition of P2RX4 curtails tumor growth and metastasis12. Significantly, P2RX4-mediated ATP signaling is involved in T-cell migration9, while it propels mammary cancer progression by sustaining autophagy and related mesenchymal transition in breast cancer (BRCA)13. However, existing research is fragmented, focusing on isolated cancer types without systematic exploration of its pan-cancer expression patterns, prognostic significance, or immune interactions. A comprehensive analysis of P2RX4 across multi cancers is lacking, leaving critical gaps in understanding its universal versus context-dependent roles.  \nPan-cancer analysis is indispensable for understanding the e","cbCaipRqqfbTYChp","https://ap.wps.com/l/cbCaipRqqfbTYChp","pdf",5504171,16,"English","# Materials and methods\n## P2RX4 expression analysis","[{\"question\":\"What data sources and analyses are used to study P2RX4 across cancers?\",\"answer\":\"The study integrates expression levels, gene mutations, immune infiltration, pathway enrichment, and prognostic value using TCGA, GTEx, GEO, TIMER2, cBioportal, and Metascape, followed by analyses across 33 tumor types.\"},{\"question\":\"How was P2RX4 experimentally validated in specific cancer tissues and cell models?\",\"answer\":\"P2RX4 expression in liver hepatocellular carcinoma and paracancer samples was measured by Western blot and RT-qPCR. Functional cell studies used knockin in U251 and PC3 cells and assessed viability, apoptosis, migration, and invasion with CCK-8, flow cytometry, wound healing, and Transwell assays.\"},{\"question\":\"What clinical significance does P2RX4 show in the pan-cancer results?\",\"answer\":\"Higher P2RX4 expression is reported in most cancers and predicts poorer overall survival and disease-free survival. The expression correlates positively with cancer-associated fibroblasts and CD8+ cell infiltration, and links to unfavorable prognosis.\"}]","The role and function validation of P2RX4 as a novel cancer biomarker in pan-cancer analysis | PDF",1790159499,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5259df800c3d643ac16209062d83492.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8410fffae8bfca09b12e85e067cf4553.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3aa76544c2dbc4ac16675864f727725.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faa89c37a5d550c819468e31903f7a1e.webp",980,1287]